Onset and maintenance of the luteal phase with GnRH antagonists or hCG in cycles under GnRH antagonists;Déclenchement par agonistes de la GnRH ou hCG et soutien de la phase lutéale dans les cycles sous antagonistes de la GnRH

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 33, Issue 6 II, 2004, Pages

  Olivennes, F ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

GnRH agonist; GnRH antagonist; hCG; Luteal phase; recLH; Triggering ovulation

Indexed keywords

CHORIONIC GONADOTROPIN; ESTROGEN; GANIRELIX; GONADORELIN ANTAGONIST; LEUPRORELIN; PROGESTERONE; RECOMBINANT LUTEINIZING HORMONE; TRIPTORELIN;

CORPUS LUTEUM FUNCTION; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; LUTEINIZING HORMONE RELEASE; LUTEOLYSIS; MENSTRUAL CYCLE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; REVIEW;

CHORIONIC GONADOTROPIN; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEAL PHASE; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PROGESTERONE;

EID: 5744231353     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Albano C, Grimbizis G, Smitz J, Riethmuller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 1998; 70: 357-9.
2. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist cetrorelix. Hum Reprod 2001; 16: 663-7.
3. Lin Y, Kahn JA, Hillensjo T. Is there a difference in the function of granulosa-luteal cells in patients undergoing in vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Hum Reprod 1999; 14: 885-8.
4. Albano C, Smitz J, Tournaye H, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in vitro fertilization/intracytoplasmic sperm injection cycles. Hum Reprod 1999; 14: 1426-30.
5. Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, Crosignani PG. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum Reprod 2001; 16: 2258-62.
6. Itskovitz J, Hodgen GD. Endocrine basis for the initiation, maintenance and termination of pregnancy in humans. Psychoneuroendocrinology 1988; 13: 155-70.
7. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990; 71: 918-22.
8. Emperaire JC, Ruffie A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum Reprod 1991; 6: 506-10.
9. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56: 213-20.
10. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87: 709-15.
11. Nevo O, Erdar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil Steril 2003; 79: 1123-8.
12. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril 1996; 66: 151-3.
13. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 2000; 15: 1965-8.
14. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186-92.
15. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004; 81: 1-5.